bpc-157 human clinical evidence safety fda warning Legal Status: Regulations and Compounding bpc-157 safety evidence human clinical

In preclinical studies, it has demonstrated a compelling range of effects, most notably its ability to promote angiogenesis

The numbers consistently show reductions in the 1-3 inch range for most body areas after minimally invasive procedures

Use protecting storage containers which are inert and airtight to protect the peptides from degradation because of exposure to mild, moisture, or contaminants

Keep vials upright and away from light

Your confidentiality is our utmost priority

At the 0.25 mg starting dose, a single vial contains 20 weeks of doses, but the reconstituted solution will degrade before you use it all